MIAMI--(BUSINESS WIRE)--Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the National Cancer Institute (NCI) reported study results from an extensive multi-center canine study using Gibson’s Indenoisoquinolines (LMP400, LMP766, and LMP744) to treat 84 dogs with advanced stages of lymphoma.
Importantly, both LMP400 and LMP766 have already completed 4 Phase I studies in cancer patient with solid tumors and LMP744 recently entered phase I studies supported by the NCI based on the favorable results from this canine study. All these efforts were derived from discoveries by Professor Mark Cushman of Purdue University and Dr. Yves Pommier at the National Cancer Institute of the NIH.
“All three drugs are very active,” says Yves Pommier, M.D., Ph.D., Chief of CCR’s Developmental Therapeutics Branch. The findings appeared online July 30, 2018, in Clinical Cancer Research.
Among dogs who received LMP744, “tumors shrank significantly in about 80 percent of treated dogs. The drug was effective even at low doses…We didn’t expect it to be that potent,” Pommier says. LMP744 may have worked well because it accumulated at high concentrations in the tumors, analyses suggest. The link to access the publication of this study is listed below.
http://clincancerres.aacrjournals.org/content/early/2018/07/28/1078-0432.CCR-18-1498
Mr. Randall Riggs, President & CEO of Gibson Oncology, stated that “this work is sufficiently important that the NCI published the results and also published an article about it in the NIH CCR News. We are pleased that this study further confirms the efficacy and safety of Gibson Oncology’s novel anti-cancer drugs and provides us additional confidence, beyond the 4 completed phase I clinical trials and the new ongoing phase I trial with LMP744, as we prepare to initiate phase II trials in adult and pediatric cancers.”
About Gibson
Gibson is a private oncology drug development company dedicated to bringing its novel, cost-effective, and very well-tolerated Indeno anti-cancer treatments to market. Gibson intends to develop these novel anti-cancer drugs in advanced-stage cancer patients as single agent and in combination treatments with both immunotherapy and targeted therapies.
